Sinclair Pharma PLC (LON:SPH)‘s stock had its “buy” rating reiterated by equities researchers at Peel Hunt in a research report issued to clients and investors on Monday. They presently have a GBX 68 ($0.87) target price on the specialty pharmaceutical company’s stock. Peel Hunt’s price target would indicate a potential upside of 124.79% from the stock’s current price.

Other equities analysts also recently issued reports about the stock. Stifel Nicolaus restated a “buy” rating and set a GBX 71 ($0.90) target price on shares of Sinclair Pharma PLC in a report on Tuesday, April 4th. N+1 Singer dropped their target price on shares of Sinclair Pharma PLC from GBX 42 ($0.54) to GBX 37 ($0.47) and set a “buy” rating for the company in a report on Wednesday, April 19th. Jefferies Group LLC restated a “buy” rating and set a GBX 55 ($0.70) target price on shares of Sinclair Pharma PLC in a report on Wednesday, March 22nd. Finally, Numis Securities Ltd restated a “hold” rating and set a GBX 35 ($0.45) target price on shares of Sinclair Pharma PLC in a report on Tuesday, April 4th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. Sinclair Pharma PLC presently has a consensus rating of “Buy” and a consensus price target of GBX 54 ($0.69).

Analyst Recommendations for Sinclair Pharma PLC (LON:SPH)

Shares of Sinclair Pharma PLC (LON:SPH) traded up 0.83% during midday trading on Monday, reaching GBX 30.25. 49,471 shares of the company’s stock traded hands. The firm’s 50-day moving average price is GBX 32.49 and its 200 day moving average price is GBX 32.38. The stock’s market capitalization is GBX 151.91 million. Sinclair Pharma PLC has a 1-year low of GBX 26.00 and a 1-year high of GBX 36.35.

ILLEGAL ACTIVITY WARNING: This news story was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright & trademark legislation. The original version of this news story can be viewed at https://www.americanbankingnews.com/2017/06/19/sinclair-pharma-plcs-sph-buy-rating-reaffirmed-at-peel-hunt.html.

Sinclair Pharma PLC Company Profile

Sinclair Pharma plc, formerly Sinclair IS Pharma plc, is a United Kingdom-based specialty pharmaceutical company. The Company is engaged in the manufacture and wholesale distribution of dermatological products. Its segments are Country Operations, which include its operations in France, the United Kingdom, Italy, Germany and Spain, and International Operations, under which the Company sells through a local distributor.

Receive News & Ratings for Sinclair Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sinclair Pharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.